Ken Cacciatore
Stock Analyst at TD Cowen
(0.34)
# 4,254
Out of 5,065 analysts
12
Total ratings
30%
Success rate
-28.61%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $29.49 | +69.55% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $6.03 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $14.30 | +39.86% | 4 | May 16, 2023 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $15.07 | +132.25% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $4.20 | +1,090.48% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $7.26 | +588.71% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $9.69 | +364.40% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $16.38 | +2,708.30% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $29.49
Upside: +69.55%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.03
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $14.30
Upside: +39.86%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $15.07
Upside: +132.25%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $4.20
Upside: +1,090.48%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $7.26
Upside: +588.71%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $9.69
Upside: +364.40%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $16.38
Upside: +2,708.30%